Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an announcement.
Argenica Therapeutics Limited has announced its Annual General Meeting (AGM) will be held on November 12, 2025, in Perth. The announcement outlines the deadline for director nominations, which must be submitted by September 24, 2025. This meeting is significant for stakeholders as it will address key resolutions impacting the company’s future governance and strategic direction.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited operates in the biotechnology industry, focusing on developing novel therapeutics. The company is primarily engaged in creating treatments aimed at reducing brain damage after stroke, positioning itself as a key player in the medical innovation market.
Average Trading Volume: 474,899
Technical Sentiment Signal: Sell
For detailed information about AGN stock, go to TipRanks’ Stock Analysis page.